Screener
Candel Therapeutics, Inc. CADL Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-222904
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $9,840 | $4,016 |
| General and administrative | 6,444 | 4,114 |
| Total operating expenses | 16,284 | 8,130 |
| Loss from operations | (16,284) | (8,130) |
| Other income (expense): | ||
| Grant income | 22 | — |
| Interest income | 1,322 | 934 |
Item 1. Financial Statements.
FAQ
- What is Candel Therapeutics, Inc.'s other operating expenses?
- Candel Therapeutics, Inc. (CADL) reported other operating expenses of $16.28M in Q1 2026.
- How has Candel Therapeutics, Inc.'s other operating expenses changed year-over-year?
- Candel Therapeutics, Inc.'s other operating expenses increased by 100.3% year-over-year, from $8.13M to $16.28M.
- What is the long-term trend for Candel Therapeutics, Inc.'s other operating expenses?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s other operating expenses has grown at a 16.9% compound annual growth rate (CAGR), from $25.85M to $48.27M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Candel Therapeutics, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude